Related Experiment Video
Updated: Sep 3, 2026
Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice
Published on: September 25, 2013
Somatostatin receptor 1 (SSTR1) and somatostatin receptor 5 (SSTR5)expression in hepatocellular carcinoma
Background/Aims:
Somatostatin analogues are considered for the treatment of advanced hepatocellular carcinomas which express somatostatin receptors (SSTR). There is limited data for the SSTR subtypes. Somatostatin receptor 1 (SSTR1) and Somatostatin receptor 5 (SSTR5) expressions are investigated in needle biopsy materials of patients diagnosed as hepatocellular carcinoma, using immunohistochemical methods in the assistance of antibody kits.
Methodology:
The needle biopsy materials of forty-one patients that were diagnosed as hepatocellular carcinoma between 2000 and 2006 have been examined. The underlying diseases, 4FP values, treatments received and the sections were evaluated after SSTR1 and SSTR5 staining.
Results:
SSTR1 expression was found in 31 (75.6%) and SSTR5 expression in 21 of (51.2%) 41 biopsies. SSTR1 and SSTR5 expressions were not determined in 10 (24.4%) and 20 (48.8%) of the cases. In addition, no significant correlation of the SSTR1 and SSTR5 stains with the underlying diseases (chronic hepatitis and cirrhosis) and gender was observed.
Conclusions:
This study demonstrated that the tumor cells in the tissue samples of the patients diagnosed with advanced-stage hepatocellular carcinoma expressed a high proportion of SSTR1 and SSTR5.
Insights
Advanced hepatocellular carcinoma (HCC) patients frequently express somatostatin receptor 1 (SSTR1) and somatostatin receptor 5 (SSTR5) in tumor cells. This finding supports the potential use of somatostatin analogues for HCC treatment.
Area of Science:
- Oncology
- Gastroenterology
- Molecular Biology
Background:
- Somatostatin analogues are potential treatments for advanced hepatocellular carcinoma (HCC).
- Expression data for specific somatostatin receptor (SSTR) subtypes in HCC is limited.
- Investigating SSTR1 and SSTR5 expression is crucial for targeted therapy development.
Purpose of the Study:
- To investigate the expression of somatostatin receptor 1 (SSTR1) and somatostatin receptor 5 (SSTR5) in hepatocellular carcinoma (HCC) tissues.
- To determine the prevalence of SSTR1 and SSTR5 in HCC needle biopsy samples.
- To assess the correlation of SSTR expression with underlying diseases and patient gender.
Main Methods:
- Immunohistochemical analysis of SSTR1 and SSTR5 expression.
- Examination of needle biopsy materials from 41 HCC patients diagnosed between 2000 and 2006.
- Evaluation of underlying diseases, AFP levels, and treatments alongside receptor staining.
Main Results:
- SSTR1 expression was detected in 75.6% (31/41) of HCC biopsies.
- SSTR5 expression was found in 51.2% (21/41) of HCC biopsies.
- No significant correlation was observed between SSTR1/SSTR5 expression and underlying liver diseases (chronic hepatitis, cirrhosis) or gender.
Conclusions:
- Tumor cells in advanced HCC exhibit a high proportion of SSTR1 and SSTR5 expression.
- These findings support the potential utility of somatostatin analogues targeting SSTR1 and SSTR5 in HCC treatment.
- Further research into SSTR subtype expression can refine targeted therapeutic strategies for HCC.
